We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
3
0 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
1989
Unknown
100.0%
No approval data available
- The UK government has renewed the Biomedical Catalyst and launched new funding programs including the Life Sciences Transformational R&D Investment Fund (TRIF) Pilot and Growth Catalyst, totaling over £100 million to support high-risk, high-reward pharmaceutical and biotech projects. - These targeted investments aim to address the UK's declining pharma R&D investment since 2020 and strengthen domestic manufacturing resilience for advanced therapies, vaccines, and critical healthcare products following pandemic supply chain vulnerabilities. - The funding initiative represents a strategic intervention to maintain the UK's competitive position against intensifying global competition from the US and EU, focusing on transformational projects in AI-enabled drug discovery, cell and gene therapy manufacturing, and sustainable vaccine platforms. - Industry experts emphasize the critical timing of these investments, as UK companies often relocate to the US for commercialization due to capital constraints, with successful examples like Humira generating billions for the American economy after leaving British development programs.
